載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$6.06
+US$0.02 · +0.33%
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
前收盤價
US$6.06
+US$0.02 · +0.33%
盤後
US$5.8879
−US$0.1721 · -2.84%
10月7日 下午7:34 ET
盤中時間採用ET。市場資料可能有所延遲。
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
日內區間
目前US$6.06
52週區間
目前US$6.06
盤中時間採用ET。市場資料可能有所延遲。
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
日內區間
目前US$6.06
52週區間
目前US$6.06
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 185萬 USD | 319.03萬 USD | 500.37萬 USD | 655.42萬 USD | 548.25萬 USD |
| 銷售、一般及管理費用 | 391.31萬 USD | 762.69萬 USD | 551.7萬 USD | 660.34萬 USD | 601.58萬 USD |
| 營業費用 | 576.31萬 USD | 1081.71萬 USD | 1052.07萬 USD | 1315.76萬 USD | 1149.83萬 USD |
| 利息支出 | — | — | — | 2.15萬 USD | — |
| 折舊和攤銷 | 15.73萬 USD | 20.62萬 USD | 27.55萬 USD | 23.43萬 USD | 22.44萬 USD |
| 營業利益 | −576.31萬 USD | −1081.71萬 USD | −1052.07萬 USD | −1315.76萬 USD | −1149.83萬 USD |
| 淨利 | −702.74萬 USD | −1150.79萬 USD | −1006.03萬 USD | −1317.91萬 USD | −1123.13萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅4項
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
